{"id":"preservative-free-drop-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Transient blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Preservative-free drops eliminate the use of antimicrobial agents (such as benzalkonium chloride) that can cause ocular surface irritation and toxicity with chronic use. This formulation is typically delivered via single-dose units or special packaging systems that maintain sterility without preservatives, reducing local toxicity while maintaining therapeutic efficacy for the active ingredient.","oneSentence":"A preservative-free ophthalmic drop formulation that delivers therapeutic agents directly to the eye without chemical preservatives.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:36:33.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Glaucoma (preservative-free formulation)"},{"name":"Allergic conjunctivitis"},{"name":"Post-operative ocular care"}]},"trialDetails":[{"nctId":"NCT07243275","phase":"PHASE4","title":"SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease","status":"RECRUITING","sponsor":"Indiana University","startDate":"2026-02-18","conditions":"Dry Eye Disease (DED)","enrollment":260},{"nctId":"NCT06544694","phase":"PHASE3","title":"A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-10-08","conditions":"Dry Eye Disease","enrollment":80},{"nctId":"NCT07151612","phase":"PHASE4","title":"The Development of New Functions of Esculin and Digitalis Glycosides Eye Drops: A Study on the Treatment of Presbyopia","status":"COMPLETED","sponsor":"Shanxi Eye Hospital","startDate":"2025-09-04","conditions":"Presbyopia","enrollment":62},{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT06660290","phase":"PHASE3","title":"A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2025-01-15","conditions":"Dry Eye Disease","enrollment":55},{"nctId":"NCT07469865","phase":"NA","title":"Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2021-11-30","conditions":"Dry Eye Disease","enrollment":46},{"nctId":"NCT05945615","phase":"PHASE3","title":"Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2024-01-11","conditions":"Blepharoptosis, Synkinesis, Hyperkinesis","enrollment":36},{"nctId":"NCT06190028","phase":"NA","title":"Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy","status":"TERMINATED","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2023-06-14","conditions":"Dry Eye Syndrome, Glaucoma and Concomitant Dry Eye Syndrome, Ocular Hypertension and Concomitant Dry Eye Syndrome","enrollment":65},{"nctId":"NCT07394257","phase":"NA","title":"Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-10-01","conditions":"Bacterial Keratitis, Recalcitrant Infectious Keratitis, Corneal Ulcer","enrollment":60},{"nctId":"NCT04505566","phase":"PHASE1","title":"INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stephen J. Kim, MD","startDate":"2020-11-09","conditions":"Diabetic Retinopathy","enrollment":164},{"nctId":"NCT06394973","phase":"PHASE2","title":"Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2024-08-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":161},{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT04125134","phase":"PHASE4","title":"Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2019-10-03","conditions":"Dry Eye","enrollment":36},{"nctId":"NCT07064187","phase":"PHASE4","title":"Evaluate The Improvement In Symptoms Of Patients Using Cationorm After Pterygium Surgery","status":"COMPLETED","sponsor":"Nguyen Viet Giap","startDate":"2022-06-15","conditions":"Ocular Discomfort","enrollment":100},{"nctId":"NCT05682547","phase":"NA","title":"Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye","status":"COMPLETED","sponsor":"He Eye Hospital","startDate":"2022-12-01","conditions":"Diabetic Eye Problems","enrollment":99},{"nctId":"NCT03162497","phase":"PHASE4","title":"Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2018-01-08","conditions":"Dry Eye Syndromes, Meibomian Gland Dysfunction","enrollment":23},{"nctId":"NCT06921525","phase":"PHASE1, PHASE2","title":"Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Ehab Mohamed Elsayed Mohamed Saad","startDate":"2025-04-01","conditions":"Dry Eye","enrollment":44},{"nctId":"NCT05705518","phase":"PHASE4","title":"Artificial Tears, Tear Lipids and Tear Film Dynamics","status":"COMPLETED","sponsor":"University of California, Berkeley","startDate":"2023-01-30","conditions":"Dry Eye","enrollment":81},{"nctId":"NCT03193333","phase":"PHASE3","title":"PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-11-06","conditions":"Primary Open-angle Glaucoma","enrollment":51},{"nctId":"NCT06671041","phase":"PHASE4","title":"Treating Lid Wiper Epitheliopathy","status":"COMPLETED","sponsor":"Southern College of Optometry","startDate":"2024-05-27","conditions":"Dry Eye, Visual Acuity","enrollment":52},{"nctId":"NCT06798025","phase":"NA","title":"Three Different Modalities for Treatment of Inflammatory Punctal Stenosis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-07-20","conditions":"Modalities, Treatment, Inflammatory Punctal Stenosis","enrollment":60},{"nctId":"NCT06249152","phase":"PHASE2","title":"Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2024-04-21","conditions":"Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma","enrollment":36},{"nctId":"NCT04050644","phase":"PHASE4","title":"Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2018-10-30","conditions":"Age-related Cataract","enrollment":100},{"nctId":"NCT04133311","phase":"PHASE3","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-04-10","conditions":"Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease","enrollment":386},{"nctId":"NCT03653650","phase":"NA","title":"Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects","status":"RECRUITING","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2018-08-30","conditions":"Persistent Epithelial Defect","enrollment":54},{"nctId":"NCT04327999","phase":"PHASE2","title":"Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System","status":"TERMINATED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2020-10-05","conditions":"Thyroid Carcinoma, Radioactive Iodine Level","enrollment":9},{"nctId":"NCT04515329","phase":"PHASE4","title":"Tear Film Markers in Dry Eye Syndrome","status":"WITHDRAWN","sponsor":"Vishal Jhanji","startDate":"2023-12-08","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT06159569","phase":"NA","title":"Performance and Tolerability of the Medical Device LACRIACT","status":"COMPLETED","sponsor":"Laboratórios Baldacci S.A","startDate":"2021-09-09","conditions":"Dry Eye, Contact Lens Acute Red Eye, Photophobia","enrollment":20},{"nctId":"NCT06162442","phase":"","title":"Management of the Ocular Surface With Preservative-Free Lubricants in Patients With Dry Eye","status":"UNKNOWN","sponsor":"Tecnoquimicas","startDate":"2023-03-15","conditions":"Dry Eye Disease","enrollment":132},{"nctId":"NCT06148428","phase":"","title":"Anxiety-related Fixation Instability During LASIK","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-08-15","conditions":"Refractive Errors","enrollment":2435},{"nctId":"NCT04465071","phase":"NA","title":"Lubricating Eye Drops After Routine Cataract Surgery","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2020-02-24","conditions":"Dry Eye, Cataract","enrollment":79},{"nctId":"NCT05618730","phase":"PHASE1","title":"Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B","status":"UNKNOWN","sponsor":"Eximore Ltd.","startDate":"2022-09-29","conditions":"Dry Eye, Keratoconjunctivitis Sicca, Ocular Inflammation","enrollment":20},{"nctId":"NCT05660681","phase":"NA","title":"Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops","status":"COMPLETED","sponsor":"Calm Water Therapeutics LLC","startDate":"2022-12-12","conditions":"Dry Eye Disease","enrollment":34},{"nctId":"NCT02600429","phase":"PHASE3","title":"Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1","status":"TERMINATED","sponsor":"ReGenTree, LLC","startDate":"2015-09-17","conditions":"Neurotrophic Keratopathy","enrollment":18},{"nctId":"NCT03822559","phase":"PHASE3","title":"A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2019-01-20","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":219},{"nctId":"NCT05940376","phase":"","title":"Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy","status":"UNKNOWN","sponsor":"Benha University","startDate":"2023-07-15","conditions":"Corneal Ulcer, Neurotrophic Corneal Ulcer, Diabetes Mellitus","enrollment":30},{"nctId":"NCT05733741","phase":"PHASE4","title":"Preservative-free Topical Anesthetics for Post-PRK Pain","status":"COMPLETED","sponsor":"Assiut University","startDate":"2023-01-30","conditions":"Myopia","enrollment":70},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT05292755","phase":"PHASE4","title":"Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome","status":"COMPLETED","sponsor":"University of Florida","startDate":"2022-04-22","conditions":"Dry Eye Syndromes","enrollment":80},{"nctId":"NCT04980144","phase":"NA","title":"Diquafosol Ophthalmic Solution for Dry Eye Symptoms","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-03-03","conditions":"Diabetic Eye Problems","enrollment":101},{"nctId":"NCT03803748","phase":"NA","title":"A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi®","status":"COMPLETED","sponsor":"SIFI SpA","startDate":"2019-07-17","conditions":"Dry Eye Syndromes","enrollment":96},{"nctId":"NCT05606796","phase":"PHASE4","title":"Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.","status":"UNKNOWN","sponsor":"Uzoma Chinyei Joan","startDate":"2022-12","conditions":"Effect of Drug","enrollment":76},{"nctId":"NCT04054830","phase":"PHASE4","title":"Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy.","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2019-08-01","conditions":"Glaucoma","enrollment":70},{"nctId":"NCT05564832","phase":"EARLY_PHASE1","title":"Pharmacological Treatment of Presbyopia","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2022-08-01","conditions":"Near Vision","enrollment":75},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT05429229","phase":"PHASE2","title":"Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Adolfo Daniel Rodriguez-Carrizalez","startDate":"2021-11-01","conditions":"Dry Eye Syndromes, Diabetic Retinopathy, Oxidative Stress","enrollment":78},{"nctId":"NCT05433428","phase":"PHASE4","title":"Metabolomic Profile in Dry Eye Syndrome Patients.","status":"UNKNOWN","sponsor":"Ifocus Oyeklinikk","startDate":"2020-08-03","conditions":"Dry Eye Syndromes, Cataract","enrollment":250},{"nctId":"NCT03803722","phase":"NA","title":"To Demonstrate the Non-inferiority of Eyestil Protection® Compared to Vismed® in Terms of Clinical Performance","status":"TERMINATED","sponsor":"SIFI SpA","startDate":"2019-07-08","conditions":"Dry Eye Syndrome","enrollment":21},{"nctId":"NCT03937882","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2019-05-24","conditions":"Dry Eye Syndromes, Dry Eye","enrollment":700},{"nctId":"NCT02533154","phase":"PHASE4","title":"Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2015-07-27","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT02974907","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2016-11","conditions":"Dry Eye Syndrome","enrollment":601},{"nctId":"NCT05064189","phase":"NA","title":"Protection of Corneal Epithelium Using Chitosan-N-acetylcysteine Eye Drops During and/or After Cataract Surgery","status":"COMPLETED","sponsor":"Vienna Institute for Research in Ocular Surgery","startDate":"2021-04-14","conditions":"Eye Diseases","enrollment":45},{"nctId":"NCT05053789","phase":"NA","title":"Efficacy of Different Treatment Regimens With Chitosan-N- Acetylcysteine in Moderate-to-severe Dry Eye Disease","status":"TERMINATED","sponsor":"Vienna Institute for Research in Ocular Surgery","startDate":"2021-05-12","conditions":"Eye Diseases","enrollment":48},{"nctId":"NCT03640650","phase":"PHASE4","title":"Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.","status":"TERMINATED","sponsor":"PeriPharm","startDate":"2018-08-15","conditions":"Cataract Surgery","enrollment":80},{"nctId":"NCT05049642","phase":"NA","title":"Effect of Chitosan-N-acetylcysteine on Subjective Pain Sensation in Corneal Abrasion","status":"TERMINATED","sponsor":"Vienna Institute for Research in Ocular Surgery","startDate":"2021-05-12","conditions":"Eye Diseases","enrollment":30},{"nctId":"NCT05028907","phase":"PHASE4","title":"Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis","status":"COMPLETED","sponsor":"Sohag University","startDate":"2020-11-15","conditions":"Ophthalmopathy , Lacrimal System","enrollment":64},{"nctId":"NCT04891588","phase":"NA","title":"Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD","status":"UNKNOWN","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-03-08","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension","enrollment":50},{"nctId":"NCT03612817","phase":"PHASE4","title":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":"Glaucoma, Open-Angle","enrollment":42},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT04485533","phase":"NA","title":"Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED","status":"UNKNOWN","sponsor":"VISUfarma SpA","startDate":"2020-07-06","conditions":"Dry Eye Syndromes","enrollment":90},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT03569202","phase":"NA","title":"Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2018-05-21","conditions":"Dry Eye Syndrome","enrollment":64},{"nctId":"NCT04131335","phase":"NA","title":"Use of Prophylactic Lubricating Drops After Cataract Surgery","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2019-10-14","conditions":"Dry Eye, Cataract Surgery, Patient Related Outcome Measures","enrollment":168},{"nctId":"NCT02597803","phase":"PHASE2, PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2015-09","conditions":"Dry Eye Syndrome","enrollment":317},{"nctId":"NCT03524157","phase":"PHASE1","title":"Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-07-17","conditions":"Dry Eye Syndromes, Lubricant Allergy, Tear Disorder","enrollment":30},{"nctId":"NCT02420834","phase":"NA","title":"Dry Eye Treatment With Artificial Tears","status":"COMPLETED","sponsor":"Aston University","startDate":"2015-04","conditions":"Dry Eye","enrollment":50},{"nctId":"NCT02417116","phase":"NA","title":"Tear Osmolarity Clinical Utility in Dry Eye Disease","status":"COMPLETED","sponsor":"Aston University","startDate":"2015-06","conditions":"Dry Eye","enrollment":120},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT03666884","phase":"PHASE4","title":"The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Seref istek","startDate":"2015-10-10","conditions":"Dry Eye Syndrome","enrollment":36},{"nctId":"NCT02908282","phase":"NA","title":"Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye","status":"COMPLETED","sponsor":"TRB Chemedica AG","startDate":"2016-10","conditions":"Dry Eye Syndromes","enrollment":81},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT03480295","phase":"NA","title":"Effects of a PF Ophthalmic Solution Containing HA0.4% and TAU 0.5%","status":"COMPLETED","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2016-12-19","conditions":"Glaucoma","enrollment":39},{"nctId":"NCT01569191","phase":"PHASE4","title":"Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Aston University","startDate":"2012-03","conditions":"Hypersensitivity","enrollment":18},{"nctId":"NCT03140111","phase":"NA","title":"LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2017-10-16","conditions":"Dry Eye Syndromes, Primary Sjögren Syndrome","enrollment":12},{"nctId":"NCT03052140","phase":"NA","title":"Lamelleye vs Comparator for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Glasgow Caledonian University","startDate":"2017-02-21","conditions":"Dry Eye Syndromes","enrollment":31},{"nctId":"NCT01228149","phase":"PHASE4","title":"COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy","status":"COMPLETED","sponsor":"Katrin Lorenz","startDate":"2010-08","conditions":"Glaucoma","enrollment":62},{"nctId":"NCT00476593","phase":"NA","title":"Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2005-09","conditions":"Uveitis, Iritis, Iridocyclitis","enrollment":218},{"nctId":"NCT02771392","phase":"PHASE2, PHASE3","title":"Treatment of Corneal Abrasions With Topical Tetracaine","status":"UNKNOWN","sponsor":"New York Presbyterian Brooklyn Methodist Hospital","startDate":"2016-06","conditions":"Corneal Abrasion","enrollment":120},{"nctId":"NCT02471105","phase":"PHASE4","title":"Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-09","conditions":"Ocular Hypertension, Glaucoma","enrollment":67},{"nctId":"NCT02752763","phase":"PHASE4","title":"Comparison of Autologous Serum Versus Preservative Free Artificial Tear","status":"COMPLETED","sponsor":"Niğde State Hospital","startDate":"2015-10","conditions":"Dry Eye","enrollment":24},{"nctId":"NCT01967147","phase":"NA","title":"Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-02","conditions":"Dry Eye","enrollment":279},{"nctId":"NCT01393132","phase":"PHASE2","title":"Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye","status":"COMPLETED","sponsor":"Michigan Cornea Consultants, PC","startDate":"2011-03","conditions":"Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease","enrollment":9},{"nctId":"NCT01799863","phase":"PHASE2, PHASE3","title":"Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis","status":"COMPLETED","sponsor":"Fundação Altino Ventura","startDate":"2012-06","conditions":"Conjunctivitis, Viral","enrollment":50},{"nctId":"NCT02014922","phase":"PHASE4","title":"A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN)","status":"COMPLETED","sponsor":"University of Waterloo","startDate":"2013-12","conditions":"Dry Eye Syndromes","enrollment":33},{"nctId":"NCT01510145","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-02","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":191},{"nctId":"NCT01493427","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":202},{"nctId":"NCT01087489","phase":"NA","title":"Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye","status":"COMPLETED","sponsor":"Miami VA Healthcare System","startDate":"2010-04","conditions":"Pain","enrollment":53},{"nctId":"NCT01434888","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-09","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT01306461","phase":"PHASE3","title":"Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-03","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":401},{"nctId":"NCT00777322","phase":"NA","title":"T-Cat Laser & Cross-linking for Keratoconus","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2008-10","conditions":"Keratoconus, Pellucid Marginal Degeneration","enrollment":15},{"nctId":"NCT01105221","phase":"PHASE3","title":"Acupuncture for Dry Eye","status":"COMPLETED","sponsor":"Korea Institute of Oriental Medicine","startDate":"2010-04","conditions":"Dry Eye","enrollment":150},{"nctId":"NCT01075347","phase":"PHASE1","title":"Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-03","conditions":"Corneal Epithelial Defect, Diabetic Retinopathy, Penetrating Keratoplasty","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Preservative Free drop treatment","genericName":"Preservative Free drop treatment","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A preservative-free ophthalmic drop formulation that delivers therapeutic agents directly to the eye without chemical preservatives. Used for Dry eye disease, Glaucoma (preservative-free formulation), Allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}